Opko Health Reports Strong Q2 Earnings, Driving Over 33% Surge in Share Price
On July 28, 2026, Opko Health (NASDAQ: OPK) saw its stock surge over 33%, driven by better-than-expected second-quarter results and an upward revision of full-year guidance. The company reported revenue of $163.5 million for the quarter, a 4% year-over-year increase, with a significantly reduced net loss of $8.4 million ($0.01 per share), compared to a prior-year loss exceeding $148 million. The improvement was largely attributed to strong performance in Opko's pharmaceuticals segment, which saw revenue rise from under $56 million to $89 million due to higher sales and a licensing deal gain of $29.4 million. Although diagnostics revenue declined year-over-year, the prior period included oncology assets that were divested in September 2025. Opko also raised its full-year revenue guidance from $530–$560 million to $560–$585 million — well above analyst expectations of around $537 million. The company is now seen as leaner and more focused, with a potential path toward profitability.
Tickers: $NVDA
Topics: diagnostics pharmaceuticals revenue_growth stock_movement